What is mTOR pathway theory?
What is mTOR pathway theory?
The mechanistic target of rapamycin (mTOR) network is an evolutionary conserved signaling hub that senses and integrates environmental and intracellular nutrient and growth factor signals to coordinate basic cellular and organismal responses such as cell growth, proliferation, apoptosis, and inflammation depending on …
What activates the mTOR pathway?
In vitro studies have shown Aβ to be an activator of the PI3K/AKT pathway, which in turn activates mTOR. In addition, applying Aβ to N2K cells increases the expression of p70S6K, a downstream target of mTOR known to have higher expression in neurons that eventually develop neurofibrillary tangles.
How do I reduce mTOR?
Metformin and resveratrol inhibit mTOR through upstream pathways, inhibiting the mitochondrial complex I activity and increasing AMPK respectively. Rapamycin, and rapalogs, on the other hand inhibit mTOR directly.
Are mTOR and tor the same?
The mammalian TOR (mTOR) was identified later, when multiple groups cloned the mTOR gene in mouse, human and rat. TOR is present in at least two unique complexes with other proteins, TOR complex 1 (TORC1) and TOR complex 2 (TORC2).
How does rapamycin-fkbp12 bind to mTOR Complex 1?
The rapamycin-FKBP12 complex binds to mTOR Complex 1 (mTORC1) and interferes with its kinase function to inhibit cytokine stimulated protein synthesis (S Barik, 2006; Duré & Macian, 2009; Inoki, Ouyang, Li, & Guan, 2005; Waickman & Powell, 2012 ).
What is the role of FKBP4 in immune Regula-tion?
FKBP4, also known as FKBP52, is a member of the immunophilin family, which plays a role in immune regula- tion, protein folding, and transportation. The encoded protein of FKBP4 is a cis-trans-proline isomerase, which can interact with immunosuppressant FK506and rapamycin [4].
How is FKBP4 used to treat NSCLC cancer?
In vivo, FKBP4 can promote NSCLC tumor growth. Furthermore, FKBP4 can promote Akt and mTOR phosphorylation and activate the Akt/mTOR signaling pathway and an mTOR inhibitor can neutralize the functions of FKBP4 in NSCLC cells.
How does FKBP4 affect the progression of breast cancer?
Here we demonstrate for the first time that FKBP4 is associated with breast cancer progression and prognosis, especially of ER-negative breast cancer. We observed that inhibition of FKBP4 expression alters cell growth in a triple negative (ER-, PR-, and HER2-negative) breast cancer cell model and a murine xenograft tumor model.
